Alaunos Therapeutics, Inc. short interest in 2024
In 2024, Alaunos Therapeutics, Inc.'s disclosed short interest ran from 11.44% of shares outstanding on 12 Jan 2024 to 6.78% on 31 Dec 2024, a change of -4.66 percentage points. The year's high was 11.44% on 12 Jan 2024 and its low 6.78% on 31 Dec 2024, averaging 8.77% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 67.75 days on 14 Jun 2024. Full history: Alaunos Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 11.44% (12 Jan 2024)
- End of year
- 6.78% (31 Dec 2024)
- Change
- -4.66 pp
- High
- 11.44% (12 Jan 2024)
- Low
- 6.78% (31 Dec 2024)
- Average
- 8.77%
- Highest days to cover
- 67.75 (14 Jun 2024)
- SEC filings marked
- 5
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 11.44% | 2.49 | |
| 31 Jan 2024 | 10.64% | 6.79 | |
| 28 Mar 2024 | 9.49% | 23.98 | |
| 15 Apr 2024 | 9.14% | 25.06 | 10-K filed |
| 30 Apr 2024 | 9.16% | 33.32 | |
| 15 May 2024 | 9.07% | 47.40 | 10-Q filed |
| 31 May 2024 | 8.88% | 29.25 | |
| 14 Jun 2024 | 8.76% | 67.75 | |
| 28 Jun 2024 | 8.55% | 21.40 | |
| 15 Jul 2024 | 8.32% | 29.47 | |
| 15 Aug 2024 | 8.43% | 11.15 | 10-Q filed |
| 30 Aug 2024 | 8.72% | 5.18 | |
| 13 Sep 2024 | 7.87% | 14.80 | |
| 30 Sep 2024 | 8.16% | 3.03 | |
| 15 Oct 2024 | 8.26% | 9.48 | results (8-K) |
| 31 Oct 2024 | 8.70% | 11.71 | |
| 15 Nov 2024 | 8.67% | 8.09 | 10-Q filed |
| 29 Nov 2024 | 8.01% | 5.14 | |
| 13 Dec 2024 | 8.31% | 3.23 | |
| 31 Dec 2024 | 6.78% | 2.92 |
See also: Alaunos Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.